Curriculum Vitae. Acibadem Maslak Hospital Department of Medical Oncology Büyükdere Cad No:40 Maslak Istanbul TURKEY Tel:

Size: px
Start display at page:

Download "Curriculum Vitae. Acibadem Maslak Hospital Department of Medical Oncology Büyükdere Cad No:40 Maslak Istanbul TURKEY Tel:0212 3044486"

Transcription

1 Curriculum Vitae Full Name: Ozlem ER Date&Place of Birth: 1970, Izmir, TURKEY Office Contact: Academic Title&Department: Academic Qualifications: Acibadem Maslak Hospital Department of Medical Oncology Büyükdere Cad No:40 Maslak Istanbul TURKEY Tel: Associate Professor of Internal Medicine and Medical Oncology, Acibadem Maslak Hospital, Istanbul, Turkey MD, Hacettepe University Medical Faculty, Ankara, TR 1999 INTERNAL MEDICINE SPECIALIST, Ankara Numune Hospital, TR 2002 MEDICAL ONCOLOGY SPECIALIST, Erciyes University, TR MD Anderson Cancer Center, Breast Medical Oncology, USA AVON-AACR Cancer Biology Fellow, TJU, USA Academic Interests: Solid tumors- breast cancer, colorectal cancer, lung cancer-, targeted therapy, thrombosis in cancer patients Researchs/Projects: I have participated in several national and international multicenter clinical studies. Experience Abroad: MD Anderson Cancer Center, Medical Oncology Department October March 2004 (Clinical observer under supervision of Prof Gabriel N. Hortobagyi) Thomas Jefferson University, Philadelphia, PA AVON-AACR Cancer Biology Fellow Memberships: ASCO Associate Member ESMO Full Member (CERTIFICATED) Awards: AACR Member Turkish Oncology Group Member 29 th ESMO Travel Award (Vienna, 2004) Clinical Course Of Breast Cancer Patients With Liver Metastases Only Treated With Chemotherapy. Ozlem Er, Debbie Frye, Kristine Broglio, Vicente Valero, Gabriel N. Hortobagyi, Banu Arun. Journal of Thrombosis and Haemostasis 2004 Young Investigator Prize A Randomized Clinical Trial Of Combination Chemotherapy With And Without Low Molecular Weight Heparin In Small Cell Lung Cancer. Mustafa Altinbas, Hasan Senol Coskun, Ozlem Er, Metin Ozkan, Bulent Eser, Ali Unal, Mustafa Cetin, Serdar Soyuer. Avon Foundation-American Association for Cancer Research International Scholars Award in Breast Cancer Research (2006) Role of Caveolin in breast cancer pathogenesis

2 Publications A. Papers Published in Peer-Reviewed Journals : A1. Mustafa Cetin, Yusuf Ozkul, Ali Unal, Bulent Eser, Omer Ozturk, Recep Kutlubay, Ozlem Er, Hatice Burakgazi. The effect of medroxyprogesterone acetate on bone marrow and testis during cytotoxic chemotherapy. Cell Biology and Toxicology, 16, (2000) A2. Mustafa Cetin, Bulent Eser, Ozlem Er, Ali Unal, Mehmet Bilgin. Extreme thrombocytosis after penetrating femoral venous injury. Hematology, 6, (2001) A3. Bulent Eser, Mustafa Cetin, Olgun Kontas, Ali Unal, Ozlem Er, Hasan S Coskun, Mustafa Altınbas. Facial nerve paralysis and paraplagia as presenting symptoms of acute leukemia. Japan J Clin Oncol 31(2), (2001) A4. Ozlem Er, H.Senol Coskun, Mustafa Altınbas, Hulya Akgun, Mustafa Cetin, Bulent Eser, Ali Unal. Rapidly relapsing squamous cell carcinoma of renal pelvis associated with paraneoplastic syndromes of leukocytosis, thrombocytosis and hypercalcemia. Urologia Internationalis 67, (2001) A5. Mustafa Cetin, Bulent Eser, Ozlem Er, Ali Unal, Eser Kılıc, Tahir Patıroğlu, Hasan S Coskun, Mustafa Altınbas, Onder Arslan, Osman İlhan. Effects of DMSO on platelet functions and P-Selectin expression during storage. Transfusion and Apheresis Science 24, (2001) A6. Isın Soyuer, Serdar Soyuer, Ozlem Canoz, Ozlem Er, Yucel Arıtas. Correspondence. Cytopathology 13 (3), 177 (2002) A7. Berna Oksuzoğlu, Ozlem Er, Mehmet Guler,Mutlu Doğanay, Mustafa Esen, Nuri Aydın Kama. Disseminated high grade malignant lymphoma involving both of the breasts. The Breast 11: (2002) A8. Mustafa Altınbas, Ozlem Er, Metin Ozkan,Hasan S Coskun, İnci Gulmez, Eyup Ekici, Bunyamin Kaplan, Bulent Eser, Mustafa Ozesmi. Ifosfamide, mesna and interferon alfa combination chemoimmunotherapy in malignant mesothelioma:results of a single center in Central Anatolia. Medical Oncology 21(4): (2004) A9. Bunyamin Kaplan, Mustafa Altınbas, Celalettin Eroğlu, Eray Karahacıoğlu, Ozlem Er, Metin Ozkan, Mehmet Bilgin, Ozlem Canoz, İnci Gulmez, Mustafa Gulec. Preliminary results of a phase II study of weekly paclitaxel (PTX) and carboplatin (CBDCA) administered concurrently with thoracic radiation therapy (TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable non-small cell lung cancer (NSCLC). American Journal of Clinical Oncology 27 (6): (2004) A10. Metin Ozkan, Mustafa Altinbas, Ozlem Er, Bunyamin Kaplan, Hasan Senol Coskun, Eray Karahacioğlu, Ahmet Menku, Yasemin Cihan, Olgun Kontas, Hidayet Akdemir. Post-operative sequential chemoradiotherapy in high-grade cerebral gliomas with fotemustine. Journal of Chemotherapy 16 (3): (2004) A11. Metin Ozkan, Ozlem Er, Bunyamin Kaplan, Mustafa Altinbas, Bulent Ozcelik, Fatma Tokat, Edip Torun, Okkes Ibrahim Karahan. 2

3 Presentation with superior vena cava syndrome secondary to solitary lung metastasis mimicking primary lung cancer following resection of a uterine malignant mixed mullerian tumor. Eur J Obs Gyn & Rep Biol 118 (2): (2005). A12. M Ozkan, B Eser, Ozlem Er, F Altuntas, R Coskun, R Topsakal, E Mavili, M Kala, M Altinbas. Antiphospholipid syndrome associated with malignant mesothelioma presenting with superior vena cava thrombosis: A case report. Clin Appl Throm Hemos 10 (4): (2004) A13. Mustafa Altinbas, Hasan S. Coskun, Ozlem Er, Metin Ozkan, Bulent Eser, Ali Unal, Mustafa Cetin, Serdar Soyuer. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. J Throm Hemostasis 2 (8): (2004) A14. Ozlem Er, Hasan S. Coskun, Mustafa Altinbas, Metin Ozkan, Bulent Eser, Mustafa Cetin, Fevzi Altuntas, Ali Unal. Meropenem +/- granulocyte colony stimulating factor in the treatment of febrile neutropenic patients with cancer: Prospective randomized study. Journal of Chemotherapy 16 (3): (2004) A15. Bulent Eser, Fevzi Altuntas, Ozlem Er, Olgun Kontas, Ayten Ferahbas, Mustafa Cetin, Ali Unal. A case of subcutaneous panniculitis like T-cell lymphoma with hemophagocytosis secondary to chemotherapy. JEADV 18 (6): (2004) A16. Gulmez I, Kart L, Buyukoglan H, Er O, Balkanli S, Ozesmi M. Evaluation of malignant mesothelioma in central Anatolia: a study of 67 cases. Can Respir J 11(4): (2004). A17. Mustafa Altinbas, Ozlem Er, Metin Ozkan, Yusuf Solak, H. Senol Coskun, Can Kucuk, Sebnem Gursoy. Irinotecan Plus Cisplatin Combination Against Metastatic Gastric Cancer: Phase II Study. Medical Oncology 2005; 22(2): A18. Hasan Senol Coskun, Ozlem Er, Serdar Soyuer, Mustafa Altınbas, Bulent Eser,Eray Karahacioglu, Fevzi Altuntas. Solitary Plasmacytoma: Experiences From Central Anatolia. Irish J Med Sci 2005 Jan- Mar;174(1):33-6. A19. O. Er, M. Ozkan, M. Altinbas, H.S. Coskun, B. Eser, F. Altuntas, M. Cetin, A. Unal. Outpatient 5-fluorouracil+α-interferon+interleukin-2 chemoimmunotherapy in metastatic renal cell cancer patients Asia- Pacific J Clin Oncol, 1, (2005) A20. Dogu GG, Ozkan M, Er O, Eser B, Altinbas M. Squamous cell carcinoma of colorectal cancer: adjuvant radiotherapy is necessary? Eur J Cancer Care (Engl) Dec;14(5):465. A21. M. Ozkan, B. Eser, O. Er, H. S. Coskun, A. Ozturk, I. Sari, O. Canoz, M. Altinbas. Bone marrow involvement in small cell lung cancer: Prognostıc significance and correlation with hematological and biochemical parameters Asia Pacific J Clin Oncol, 2, (2006). A22. B Eser, B Kaplan, A Unal, O Canoz, F Altuntas, HI Sari, Ozlem Er, Metin Ozkan, Can Kucuk, Makbule Arar, Sebnem Gursoy, and Mustafa Cetin. Clinicopathologic Characteristics and Therapeutic Outcomes Of Primary Gastrointestinal Non-Hodgkin s Lymphomas in Central Anatolia, 3

4 in Turkey. Yonsei Medical Journal 2006 Feb 28;47 (1): A23. Eser B, Sari I, Canoz O, Altuntas F, Cakmak E, Ozturk A, Ozkan M, Er O, Cetin M, Unal A. Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma. Am J Hematol May;81(5): A24. Bulent Eser, Fevzi Altuntas, Işın Soyuer, Ozlem Er, Ozlem Canoz, Hasan S Coskun, Mustafa Cetin, Ali Unal. Acute Lymphoblastic Leukemia Associated with Brucellosis in Two Patients with Fever and Pancytopenia. Yonsei Medical Journal 2006; 47(5): A25. Nihat Kalay, Emrullah Basar, Ibrahim Ozdogru, Ozlem Er, Yakup Cetinkaya, Ali Dogan, Tugrul Inanc, Abdurrahman Oguzhan, Namik Kemal Eryol, Ramazan Topsakal, Ali Ergin. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol Dec 5;48(11): A26. Ozlem Canoz, Metın Ozkan, Vedat Arsav, Ozlem Er, HS Coskun, S Soyuer, M Altinbas. The role of c-erbb-2 expression on the survival of patients with small-cell lung cancer. Lung 2006; 184(5): A27. Ozlem Er, Leo R Zacharski. Management of cancer-associated thrombosis. Vascular Health and Risk Management 2006; 2(4): A28. M Sofikerim, I Gulmez, F Tokat, Ozlem Er, I Gulmez. Epidermoid carcinoma of the lung with isolated penile metastasis. Can J Urol Aug;14(4): A29. Yaman E, Uner A, Er O, Coskun U, Buyukberber S, Dikilitas M, Polat M, Yamac D, Kaya AO, Yildiz R, Ozturk B, Benekli M. Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer. Med Oncol. 2007;24(4): A30 Benekli M, Yildiz R, Uner A, Er O, Yamac D, Alkis N, Coskun U,Camci C, Buyukberber S. Gemcitabine plus Capecitabine Combination in Metastatic Breast Cancer Patients Previously Treated with Anthracyclines and Taxanes. Oncology. 2007;72(5-6): A31 O Er, DK Frye, SC Kau, K Broglio, V Valero, GN Hortobagyi, B Arun. Clinical Course of Breast Cancer Patients with Metastases Limited to the Liver Treated with Chemotherapy. Cancer J 2008; 14(1): A32. Coskun U, Buyukberber S, Yaman E, Uner A, Er O, Ozkan M, Dikilitas M, Oguz M, Yildiz R, B DY, Kaya AO, Benekli M. Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients. Neoplasma 2008;55(1): A33. O Er, S Mistik, M Ozkan, A Ozturk, M Altinbas. Factors related to complementary/alternative medicine use among cancer patients in Central Anatolia. Tumori 2008; 94: A34. Dogu GG, Ozkan M, Ozturk F, Dikilitas M, Er O, Ozturk A. Triplenegative breast cancer: immunohistochemical correlation with basaloid markers and prognostic value of survivin. Med Oncol Jan 21. 4

5 A35. Sotgia F, Casimiro MC, Bonuccelli G, Liu M, Whitaker-Menezes D, Er O, Daumer KM, Mercier I, Witkiewicz AK, Minetti C, Capozza F, Gormley M, Quong AA, Rui H, Frank PG, Milliman JN, Knudsen ES, Zhou J, Wang C, Pestell RG, Lisanti MP. Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation. Am J Pathol Feb;174(2): A36. Karaoglu A, Arslan UY, Ozkan M, Kalender ME, Alici S, Coskun U, Gumus M, Celenkoglu G, Er O, Sevinc A, Buyukberber S, Alkis N, Benekli M. Efficacy and toxicity of gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer. Asian Pac J Cancer Prev 2009 Jan-Mar; 10 (1): A37. Coskun U, Alkis N, Celenkoglu G, Buyukberber S, Ozkan M, Camci C, Uner A, Er O, Aslan UY, Sevinc A, Tokluoglu S, Ozturk B, Yildiz R, Benekli M; Anatolian Society of Medical Oncology. Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer. J Natl Med Assoc Aug;101(8): A38. Er O. Cancer stem cells in solid tumors. Onkologie Oct;32(10): A39. Karaca H, Lale A, Dikilitas M, Ozkan M, Er O. Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature. Med Oncol Oct 15. A40. Hasan Senol COSKUN, Mustafa ALTINBAS, Ozlem ER, Figen OZTURK, Hatice KARAMAN, Serdar SOYUER, Metin OZKAN, Isin SOYUER. Human epidermal growth factor receptor 2 oncoprotein expression in breast cancer patients from central Anatolia, Turkey. Asia Pacific Journal of Clinical Oncology 2009;5: B. Oral and Poster Presentations at International Meetings : B1. H. S. Coskun, B. Eser, M. Cetin, A.Unal, M. Altınbas, O. Er, E. Karahacıoğlu, B. Kaplan. Hodgkin Disease: results of single center in Central Anatolia of Turkey. American Society of Clinical Oncology. Thirtysixth Annual Meeting May 20-23, 2000-New Orleans, LA, USA B2. Ozlem Er, H.Senol Coskun, Mustafa Altınbas, Bulent Eser, Muzaffer Keklik, Mustafa Cetin, Eray Karahacıoğlu, Ali Unal. Efficacy of vinorelbine and doxorubicine combination chemotherapy in metastatic breast cancer. European School of Oncology 2 nd Milan Breast Cancer Congress June 14-16, 2000,Milan, Italy. B3. A Unal, M Cetin, B Eser, S Gucer, M Tayyar, O Er, HS Coskun. Activated protein C resistance in Turkish women with pre-eclampsia. 5 th Annual Meeting of the European Haematology Association, p:500, June 2000, Birmingham, UK. B4. H. Senol Coskun, Ozlem Er, Mustafa Altınbas, Fatih Tanrıverdi, Bulent Eser, Ali Unal, Mustafa Cetin. Adjuvant treatment of locally advanced gastric cancer. A retrospective analysis. 25th European Society for Medical Oncology Congress, October 2000, Hamburg, Germany. Annals of Oncology 2000, 11(Suppl 4): p117. B5. Ali Unal, Bulent Eser, Mustafa Cetin, Mustafa Altınbas, Eray 5

6 Karahacıoğlu, Olgun Kontas, Bunyamin Kaplan, Ozlem Er, Senol Coskun. Clinico-pathologic characteristics of non-hodgkins lymphoma patients at single center in Central Anatolia. 25th European Society for Medical Oncology Congress, October 2000, Hamburg Germany. Annals of Oncology 2000, 11(Suppl 4): 102. B6. M Altınbas, HS Coskun, O. Er, M Ozkan, B Eser, A Unal, M Cetin. Prospective randomized study of epirubicine cyclophosphamide and vincristine combination chemotherapy (CEV) + low molecular weight heparin (LMWH) in small cell lung cancer. Proceedings of ASCO VOL ; 321a. B7. Ozlem Er, HS Coskun, M.Altınbas, B.Eser, M.Cetin, A.Unal. Epidemiological characteristics and results of adjuvant treatment of colorectal cancer patients from Erciyes University Oncology Hospital in Turkey. Proceedings of ASCO vol ;114b B8. Ozlem Er, HS Coskun, M.Altınbas, İ.Gulmez, B.Eser, M.Cetin, A.Unal. Cisplatin and etoposide versus cisplatin and vinorelbine:a retrospective comparison in patients with advanced nonsmall cell lung cancer. International Symposium Lung Cancer and Bronchoscopy 29 Aug-1Sep B9. M.Altınbas, O. Er, HS Coskun, S.Soyuer, A.Unal, E,Karahacıoğlu. Palliative chemotherapy in inoperable or metastatic pancreatic carcinoma. 4th International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies Sep 6-8,2001; 84. B10. M.Altınbas, O. Er, HS Coskun, E.Ekici, İ.Gulmez, M.Ozesmi. Ifosfamide, mesna and interferon alfa combination therapy in malignant mesothelioma:results of a single center in central anatolia, Turkey. European J Cancer 2001: vol 37 sup 6; B11. HS Coskun, O. Er, M.Altınbas, B.Eser, A.Unal, M.Cetin. Efficacy of cisplatin etoposide combination in anthracycline refractory metastatic breast cancer. The Breast Journal 2001;7(5): 43. B12. HS Coskun, O. Er, M.Altınbas, O. Coban, M.Cetin, B.Eser. Docetaxel and doxorubicin combination in salvage therapy of metastatic breast cancer. The Breast Journal 2001;7(5): B13. Ozlem Er, HS Coskun, M.Altınbas, B.Eser, A.Unal, M.Cetin. Paclitaxel and epirubicin combination therapy in metastatic breast cancer patients. The Breast Journal 2001;7(5): 69. B14. Ozlem Er, HS Coskun, I. Soyuer, M.Altınbas. Late onset of local recurrence and distant metastases from breast cancer. The Breast Journal 2001;7(5): 71. B15. Ali Unal, Mustafa Cetin, Bulent Eser, Turkan Patıroğlu, Senol Coskun, Ozlem Er, Bunyamin Kaplan, Mustafa Altınbas. Autologous Peripheral Blood Stem Cell Transplantation In Patients with Resistant and/or Relapsing Lymphoma: Single center experience. Blood 2001; 98(11): 400b. B16. M. Altınbas, F.N. Aykan, M. Erkisi, E. Buyukunal, İ. Yucel, N. Gunel, O. Er, N, Uskent, H. Akbulut, R. Disci, H. Camlıca, D. Fırat. Alternating combination of irinotecan with 5-fluorpuracil and folinic acid in first line chemotherapy of metastatic colorectal cancer (a Turkish Oncology Group 6

7 study). American Society of Clinical Oncology. Thirty-Eighth Annual Meeting May 18-21, 2002 Orlonda FL, USA Prog Proceedings of ASCO Vol: 21, 2002 Abstract: B17. Ozlem Er, Senol Coskun, Yusuf Solak, Mustafa Altınbas. Irinotecan Plus Cisplatin Combination Against Metastatic Gastric Adenocarcinoma: Preliminary Results of Phase II Study. American Society of Clinical Oncology. Thirty-Eighth Annual Meeting May 18-21, 2002 Orlando FL, USA Prog Proceedings of ASCO Vol: 21, 2002 Abstract: B18. B.Eser, A.Unal, M. Baskol, M. Cetin, E. Cakmak, H.S. Coskun, O. Er. Elevated transaminase levels in patients with vitamin B12 Deficiency. 7 th Meeting of the European Hematology 6-9 June 2002, Italy. The Hematology Journal 2002; 3(Supply 1): 384. B19. A.Unal, B.Eser, O. Canoz, B. Kaplan, H.İ. Sarı, H.S. Coskun, O. Er, M. Altınbas, M. Cetin. Clinicopathologic characteristics and prognostics factors of primary gastrointestinal non-hodgkin s lymphoma. 7 th Meeting of the European Hematology 6-9 June 2002, Italy. The Hematology Journal 2002; 3(Supply 1): B20. Ozlem Er, Hasan Senol Coskun, M.Altınbas, Metin Ozkan, Bulent Eser, Mustafa Cetin, Fevzi Altuntas, Ali Unal. Meropenem +/- granulocyte colony stimulating factor in treatment of febrile neutropenic patients in cancer: Prospective randomized study. 27 th ESMO Congress, October, 2002: Nice, France, 5 (supp 717p):194. B21. M.Altınbas, Ozlem Er, Hasan Senol Coskun, Metin Ozkan, Bulent Eser, Mustafa Cetin, Fevzi Altuntas, Ali Unal. Gemcitabin and cisplatin in the treatment of advanced or metastatic pancreatic cancer. 27 th ESMO Congress, October, 2002: Nice, France, 5 (supp 717p):194. B22. H.Senol Coskun, Mustafa Altınbas, Ozlem ER, Figen Ozturk, Hatice Karaman, Serdar Soyuer, Metin Ozkan, Isın Soyuer. HER2 expression in Turkish breast cancer patients from a single center. 27 th ESMO Congress, October, 2002: Nice, France, 5 (supp 41p):194. B23. Ozlem Er, Yusuf Ozkul, Mustafa Altinbas, Sebnem Gursoy, H.Senol Coskun, Metin Ozkan, Serpil Tekin, Hilal Akalin. K-ras codon 12 mutations in colorectal cancer patients. American Society of Clinical Oncology Annual Meeting May 31-June 3, 2003 Chicago Illinois, USA Prog Proceedings of ASCO 2003 Vol 22 p308, no:1238 B24. Mustafa Altinbas, Metin Ozkan, Ozlem Er, Hatice Everest, H.Senol Coskun, Ahmet Menku, Yasemin Cihan, Bunyamin Kaplan. Adjuvant radiotherapy and fotemustine in treatment of anaplastic astrocytoma and glioblastoma multiforme patients. ASCO Annual Meeting May 31- June 3, 2003 Chicago Illinois, USA Prog Proceding of ASCO 2003 Vol 22, p:115, no:459 B25. Bunyamin Kaplan, Mustafa Altınbas, Celalettin Eroğlu, Eray Karahacıoğlu, Ozlem Er, Metin Ozkan, Mehmet Bilgin, Ozlem Canoz, İnci Gulmez, Mustafa Gulec. A phase II study of weekly paclitaxel (PTX) and carboplatin (CBDCA) with concurrent thoracic radiation therapy (TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable non-small cell lung cancer (NSCLC). ASCO Annual Meeting May 31-June 3, 2003 Chicago Illinois, USA Prog Proceedings of ASCO 2003 Vol 22, p:704, no:2832. B26. B Eser, F Altuntas, B Kaplan, O Canoz, M Ozkan, O Er, HS Coskun, 7

8 K Gundogan, M Cetin, A Unal. Results of first line treatment in Hodgkin s disease: Single center experience. 8 th Annual Congress of the European Haematology Association, June 2003, Lyon, France, no:0355 B27. F Altuntas, B Eser, O Canoz, O Er, M Ozkan, B Kaplan, A Sahin, M Cetin, A Unal. Fludarabine and fludarabine based combination chemotherapy in chronic lymphocytic leukemia/lymphoma. 8 th Annual Congress of the European Haematology Association, June 2003, Lyon, France, no:0623, p:190. B28. Ozlem Er, Metin Ozkan, Mustafa Altinbas, H. Senol Coskun, Bulent Eser, Fevzi Altuntas, Mustafa Cetin, Ali Unal. 5-fluorouracil+interferon alfa+ interleukin-2 chemoimmunotherapy in metastatic renal cell cancer patients. ASCO 40 th Annual Meeting 2004 New Orleans, USA Prog Proceedings of ASCO Vol 23, B29. H.S. Coskun, O. Er, M. Ozkan, B. Eser, M. Altinbas. Adjuvant sequential docetaxel and cyclophosphamide-doxorubicin combination in operable breast cancer patients. Proceedings of ASCO Vol ;81. B30. M. Altinbas, B. Kaplan, K. Ucar, M. Ozkan, E. Karahacioglu, O. Er, C. Kucuk, I. Soyuer. 5-FU plus lucovorin (Mayo Regimen) for concurrent chemoradiotherapy after surgery in patients with resectable locally advanced gastric carcinoma: Preliminary results of a phase II study. Proceeding of ASCO vol ;4196. B31. Mustafa Altinbas, Metin Ozkan, Ozlem Er, Ramazan Coskun, Bunyamin Kaplan, Oguz G. Yildiz, Bulent Eser, Ismail Sari, Ramazan Demir. Phase II study of Cisplatin-Etoposide (CE) combination chemotherapy + low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). Annals of Oncology 2004, Suppl 3 (15):162. B32. Ozlem Er, Debbie Frye, Kristine Broglio, Vicente Valero, Gabriel N. Hortobagyi, Banu Arun. Clinical Course Of Breast Cancer Patients wıth Liver Metastases Only Treated With Chemotherapy. Annals of Oncology 2004, Suppl 3 (15):42 B33. M. Ozkan, I. Sari, I. Kocyigit, O. Er, B. Eser, Y. Ozkul, G. Gokoz, M. Cetin, M. Altinbas. Trombosis in Cancer Patients (P1002), Journal of trombosis and Haemostasis, 2005, Vol3 (Suppl 8). B34. O. Er, M. Ozkan, S. Coskun, G. Dogu, M. Altinbas. Cisplatin+gemcitabine versus cisplatin+vinorelbine in patients with stage IV non-small cell lung cancer (NSCLC): Results of single center experience (P481) Lung Cancer, 49 (Suppl 2), 243 (2005). B35. I. Soyuer, S. Soyuer, K. Ucar, O. G. Yildiz, O. Orhan, M. Ozkan, O. Er, M. Altinbas, B. Kaplan Prognostic significance of CD9 and NF-κb in gastric carcinoma patients treated with surgery and adjuvant chemoradiotherapy (P2-017) XXIII. World Congress of Pathology and Laboratory Medicine 199 (2005). B36. Coşkun HŞ, Yilmaz O, Alanoğlu G, Şahin M, Er Ö, Ergürhan İlhan İ. Chemotherapy associated anemia in solid tumor patienst from Anatolia. ASCO 41 st Annual Meeting Proceedings. J Clinical Oncology 2005; 23: (16S): 729s, P: B37. M Altinbas, AT Ersozlu, M Dikilitas, GG Dogu, M Ozkan, O Er. Early osteoporosis risk in premenopausal women with breast cancer after 8

9 ovarian ablation. 31 st ESMO Congess, Annals of Oncology 2006; 17: S9: 316. B38. M Ozguroglu, T Evrensel, O Er, H Turna, T Yanmaz, O Yildiz, N Mandel, S Serdengecti. Phase II trial of a combination of weekly docetaxel and four-weekly carboplatin in the first line treatment of advanced non-small cell lung cancer. 31 st ESMO Congess, Annals of Oncology 2006; 17: S9: 756P. B39. M Ozkan, A Okur, M Dikilitas, E Mavili, O Er, GG Dogu, M Altinbas, M Gulec. The effect of concurrent chemotherapy and low molecular weight heparin (dalteparin) on tumor angiogenesis in patients with small cell lung cancer: Radiologic evaluation-preliminary results. 31 st ESMO Congress, Annals of Oncology 2006; 17: S9: 811. B40. G Demir, N Zengin, O Yildiz, G Dogusoy, F Aykan, O Er, A Isikdogan, S Turhal, U Yilmaz, Suayib Yalcin. The role of lymph nodes on disease free survival in operated gastric cancer (Turkish Oncology Group Study). 31 st ESMO Congress, Annals of Oncology 2006; 17: S9: 1100P. B41. G Demir, N Zengin, O Yildiz, S Ozdamar, F Aykan, O Er, M Ilhan, S Turhal, U Yilmaz, Suayib Yalcin. Clinical profile of gastric cancer in Turkey: Factors effecting disease free survival and relapse (Turkish Oncology Group Study). 31 st ESMO Congress, Annals of Oncology 2006; 17: S9: B42. M Ozkan, M Dikilitas, I Kocyigit, O Er, I Sari, GG Dogu, B Eser, Y Ozkul, A Unal, M Altinbas. Thrombosis and cancer:clinical, laboratuary and genetic evaluation. 31 st ESMO Congress, Annals of Oncology 2006; 17: S9: 1048P. B43. O Er, M Inanc, M Ozkan, GG Dogu, M Dikilitas, A Ozturk. Predicitive value of D-Dimer and LDH levels in response to chemoterapy in metastatic colorectal cancer patients. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No 18S, 2007: B44. B Yalcin, S Yalcin, A Buyukcelik, O Sencan, M Dogan, M Turk, F Ozdemir, A Isikdogan, O Er, H Akbulut, F Icli. Opinions of the Turkish population on cancer and being informed for the diagnosis of cancer: An opinion survey. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No 18S, 2007: B45. A Sevinc, C Camci, I Sari, ME Kalender, O Er, I Soyuer, M Dikilitas, U Yilmaz, O Sagol, A Alacacioglu. Cyclooxygenase-2 expression in gastrointestinal stromal tumors. J Clin Oncol 2008: 26 (May 20 Suppl; abstr 15643) B46. Agnieszka K. Witkiewicz, Thai H. Tran, Ozlem Er, Terry Hyslop, Hallgeir Rui. Nuclear expression of transcription factors Stat5a and Stat5b confers favorable prognosis in breast cancer. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; Abstract nr {5286} 9

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

More information

CURRICULUM VITAE. Research Interest: Bresat Cancer, Gyneocologic Cancer, Colorectal Cancer, Lung Cancer.

CURRICULUM VITAE. Research Interest: Bresat Cancer, Gyneocologic Cancer, Colorectal Cancer, Lung Cancer. CURRICULUM VITAE Personal Details Surname: KARAOGLU First Name: Aziz Akademic title/ position: Asscociate Proffessor Key Qualifications: -Internal Medicine, -Medical Oncology Research Interest: Bresat

More information

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory

More information

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10 Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage

More information

Small Cell Lung Cancer

Small Cell Lung Cancer Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually

More information

Locoregional & advanced esophagus or esophagogastric junction cancer

Locoregional & advanced esophagus or esophagogastric junction cancer Eloxatin (oxaliplatin) Prior Authorization Request (For Maryland Only) Send completed form to: Case Review Unit CVS/caremark Specialty Programs Fax: 866-249-6155 CVS/caremark administers the prescription

More information

Update on Small Cell Lung Cancer

Update on Small Cell Lung Cancer Welcome to Master Class for Oncologists Session 3: 2:45 PM - 3:30 PM Washington, DC March 28, 2009 Small Cell Lung Cancer: Best Practices & Recent Advances Speaker: Bruce E. Johnson, MD Professor of Medicine,

More information

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited

More information

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Gastric or gastroesophageal junction cancer, advanced, as first-line therapy in combination with fluoropyrimidine-based

Gastric or gastroesophageal junction cancer, advanced, as first-line therapy in combination with fluoropyrimidine-based COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Cetuximab INDICATION: chemotherapy Gastric or gastroesophageal junction cancer, advanced, as first-line therapy in combination with fluoropyrimidine-based COMPENDIA

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient

Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)

More information

POLICY A. INDICATIONS

POLICY A. INDICATIONS Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

Avastin: Glossary of key terms

Avastin: Glossary of key terms Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.

More information

Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment.

Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. 1 Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. John T. Carpenter, M.D. University of Alabama at Birmingham NP 2508 1720 Second Avenue South Birmingham, AL 35294-3300

More information

Small Cell Lung Cancer

Small Cell Lung Cancer Small Cell Lung Cancer Lung Practice Guideline Dr. Brian Dingle MSc, MD, FRCPC Approval Date: April 2007 Revised: November 2008 This guideline is a statement of consensus of the Thoracic Disease Site Team

More information

Stage I, II Non Small Cell Lung Cancer

Stage I, II Non Small Cell Lung Cancer Stage I, II Non Small Cell Lung Cancer Best Results T1 (less 3 cm) N0 80% 5 year survival No Role Adjuvant Chemotherapy Radiation Therapy Reduces Local Recurrence No Improvement in Survival 1 Staging Mediastinal

More information

Lung Cancer: More than meets the eye

Lung Cancer: More than meets the eye Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research

More information

Chapter 7: Lung Cancer

Chapter 7: Lung Cancer Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin

More information

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

Cytotoxic Therapy in Metastatic Breast Cancer

Cytotoxic Therapy in Metastatic Breast Cancer Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions

More information

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011 Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare

More information

Multidiciplinary Management of Gastrointestinal Cancers. September 5-6, 2015, Radisson Blu Hotel Sisli- Istanbul AGENDA

Multidiciplinary Management of Gastrointestinal Cancers. September 5-6, 2015, Radisson Blu Hotel Sisli- Istanbul AGENDA Multidiciplinary Management of Gastrointestinal s September 5-6, 2015, Radisson Blu Hotel Sisli- Istanbul AGENDA Saturday, 5 September 2015 08:45 Welcome and Introduction Hakan Akbulut MD. Cem Börüban

More information

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine

More information

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of

More information

Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin

Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Docetaxel INDICATION: Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide

More information

Recognizing Value in Oncology Innovation. Thomas F. Goss, PharmD, Emilie H. Picard, MS, and Andrew Tarab, MHA

Recognizing Value in Oncology Innovation. Thomas F. Goss, PharmD, Emilie H. Picard, MS, and Andrew Tarab, MHA White Paper JUNE 2012 Recognizing Value in Oncology Innovation Thomas F. Goss, PharmD, Emilie H. Picard, MS, and Andrew Tarab, MHA Boston Healthcare Associates, Inc., Boston, MA, and Washington, DC Recognizing

More information

Report series: General cancer information

Report series: General cancer information Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

More information

Malignant Lymphomas and Plasma Cell Myeloma

Malignant Lymphomas and Plasma Cell Myeloma Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations

More information

Radiation Therapy in the Treatment of

Radiation Therapy in the Treatment of Lung Cancer Radiation Therapy in the Treatment of Lung Cancer JMAJ 46(12): 537 541, 2003 Kazushige HAYAKAWA Professor and Chairman, Department of Radiology, Kitasato University School of Medicine Abstract:

More information

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3

More information

Lung cancer is not just one disease. There are two main types of lung cancer:

Lung cancer is not just one disease. There are two main types of lung cancer: 1. What is lung cancer? 2. How common is lung cancer? 3. What are the risk factors for lung cancer? 4. What are the signs and symptoms of lung cancer? 5. How is lung cancer diagnosed? 6. What are the available

More information

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Advanced Refractory Solid Tumors or Lymphomas ECOG-ACRIN EAY131 (NCI CIRB) Targeted Therapy Directed by Genetic Testing in Treating

More information

A m e r i C A n A C A d e m y o f A N T I - A G i n G M e d i c i n e

A m e r i C A n A C A d e m y o f A N T I - A G i n G M e d i c i n e VOLUME II A m e r i C A n A C A d e m y o f A N T I - A G i n G M e d i c i n e Established in 1992 www.worldhealth.net Fellowship in Integrative Cancer Therapy The American Academy of Anti-aging Medicine

More information

Stem Cell Transplantation

Stem Cell Transplantation Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance

More information

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly

More information

Emerging Drug List GEFITINIB

Emerging Drug List GEFITINIB Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:

More information

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT

More information

Small-Cell Lung Cancer: Is There a Standard Therapy?

Small-Cell Lung Cancer: Is There a Standard Therapy? Small-Cell Lung Cancer: Is There a Standard Therapy? Review Article [1] January 02, 1998 By Pieter E. Postmus, MD, PhD [2] and Egbert F. Smit, MD [3] For more than 25 years, chemotherapy has been the cornerstone

More information

Developments in Biomarker Identification and Validation for Lung Cancer

Developments in Biomarker Identification and Validation for Lung Cancer Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD Alexandre.Passioukov@eortc.be Contents Introduction Lung cancer pathogenesis NSCLC treatment options

More information

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line

More information

Pediatric Oncology for Otolaryngologists

Pediatric Oncology for Otolaryngologists Pediatric Oncology for Otolaryngologists Frederick S. Huang, M.D. Division of Hematology/Oncology Department of Pediatrics The University of Texas Medical Branch Grand Rounds Presentation to Department

More information

News Release. Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma

News Release. Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma Your Contacts News Release Merck KGaA, Darmstadt, Germany Media: Markus Talanow +49 6151 72 7144 Investor Relations +49 6151 72 3321 Pfizer Inc., New York, USA Media: Sally Beatty +1 212 733 6566 Investor

More information

Ching-Yao Yang, Yu-Wen Tien

Ching-Yao Yang, Yu-Wen Tien Ching-Yao Yang, Yu-Wen Tien Division of General Surgery, Department of Surgery, National Taiwan University Hospital Oct-30-2010 Pancreatic NET have poorer prognosis when presence of liver metastases at

More information

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone

More information

Mesothelioma. Malignant Pleural Mesothelioma

Mesothelioma. Malignant Pleural Mesothelioma Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency

More information

Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka

Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced

More information

Out-Patient Chemotherapy for Lung Cancer

Out-Patient Chemotherapy for Lung Cancer Lung Cancer Out-Patient Chemotherapy for Lung Cancer Principles and practice JMAJ 46(12): 542 546, 2003 Shuichi YONEDA Director, Department of Pulmonary Medicine, Saitama Cancer Center Abstract: Recent

More information

Update in Hematology Oncology Targeted Therapies. Mark Holguin

Update in Hematology Oncology Targeted Therapies. Mark Holguin Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007

More information

Frequency of NHL Subtypes in Adults

Frequency of NHL Subtypes in Adults Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults

More information

بسم هللا الرحمن الرحيم

بسم هللا الرحمن الرحيم بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma

More information

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div. Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under

More information

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application

More information

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade

More information

Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab

Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Carboplatin INDICATION: Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY

More information

Summary ID# 13095. Clinical Study Summary: Study H3E-EW-B012

Summary ID# 13095. Clinical Study Summary: Study H3E-EW-B012 Page 1 Summary ID# 13095 Clinical Study Summary: Study H3E-EW-B012 First-line Treatment of Non-Small Cell Lung Cancer under Routine Conditions: Observational Study on Overall Survival Date summary electronically

More information

Adjuvant Chemotherapy After Complete Resection of Non-Small Cell Lung Cancer

Adjuvant Chemotherapy After Complete Resection of Non-Small Cell Lung Cancer REVIEW ARTICLE Adjuvant Chemotherapy After Complete Resection of Non-Small Cell Lung Cancer Eckart Laack, Carsten Bokemeyer, Dieter Kurt Hossfeld SUMMARY Introduction: In non-small cell lung cancer (NSCLC)

More information

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010) MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

4-Deveci F, Akbulut HH, Çelik I, Muz MH Ilhan F. Lymphocyte Subpopulations in Pulmonary Tuberculosis Patients, Mediators Inflamm., 2006;(2);89070.

4-Deveci F, Akbulut HH, Çelik I, Muz MH Ilhan F. Lymphocyte Subpopulations in Pulmonary Tuberculosis Patients, Mediators Inflamm., 2006;(2);89070. CURRICULUM VITAE Personal Details Surname: Muz Frst Name: Mehmet Hamdi Academic title/position: Prof. Dr.- President of Chest Disease Departmant Key Qualifcations: Research Interest: Lung Cancers Đnternational

More information

Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

More information

Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART

Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized

More information

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic

More information

Medical Oncology. Rotation Goals & Objectives for rotating residents. General Objectives THE UNIVERSITY OF BRITISH COLUMBIA

Medical Oncology. Rotation Goals & Objectives for rotating residents. General Objectives THE UNIVERSITY OF BRITISH COLUMBIA THE UNIVERSITY OF BRITISH COLUMBIA Department of Urologic Sciences Faculty of Medicine Gordon & Leslie Diamond Health Care Centre Level 6, 2775 Laurel Street Vancouver, BC, Canada V5Z 1M9 Tel: (604) 875-4301

More information

Lung Cancer Treatment Guidelines

Lung Cancer Treatment Guidelines Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,

More information

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured

More information

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15 Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

MEDICAL POLICY POLICY TITLE

MEDICAL POLICY POLICY TITLE Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): Effective Date: April 15, 2008 July 1, 2009- RETIRED I. DESCRIPTION/BACKGROUND High dose chemotherapy (HDC) involves the administration

More information

Neoadjuvant radiotherapy: Necessary for treatment of rectal cancer. Shannon Acker April 4, 2011

Neoadjuvant radiotherapy: Necessary for treatment of rectal cancer. Shannon Acker April 4, 2011 Neoadjuvant radiotherapy: Necessary for treatment of rectal cancer Shannon Acker April 4, 2011 Rectal Cancer 40,870 new cases in the US in 2009 49,920 deaths from colorectal cancer Second leading cause

More information

PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA

PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA 2012 1 31,, PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA Version 1.0 2012 DIVISION OF HAEMATOLOGY / ONCOLOGY DEPARTMENT OF MEDICINE KAOHSING VETERAN GENERAL HOSPTIAL General Guide Diagnosis 1.Adequate

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

14. INTENSIVE CHEMOTHERAPY TREATMENT OF GERM CELL TUMOURS

14. INTENSIVE CHEMOTHERAPY TREATMENT OF GERM CELL TUMOURS Guidelines to be followed by centres, services and units in order to be designated as Reference Centres, Services and Units of the National Health System. as agreed by the Interterritorial Board 14. INTENSIVE

More information

Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study

Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study JBUON 2013; 18(2): 314-320 ISSN: 1107-0625 www.jbuon.com E-mail: info@jbuon.com ORIGINAL ARTICLE Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective

More information

GRANIX (tbo-filgrastim)

GRANIX (tbo-filgrastim) RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil

More information

New strategies in anticancer therapy

New strategies in anticancer therapy 癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive

More information

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the

More information

CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early

CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early April 21, 2015 CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early Opdivo Demonstrates Superior Overall Survival Compared to Docetaxel in Patients with Previously-Treated

More information

ADJUVANT TREATMENT CLINICAL EVALUATION NEOADJUVANT TREATMENT

ADJUVANT TREATMENT CLINICAL EVALUATION NEOADJUVANT TREATMENT te: Consider Clinical Trials as treatment options for eligible patients. Referral to a center with both pediatric oncology and orthopedic surgery is essential. CLINICAL EVALUATION This practice algorithm

More information

CHAPTER 6: TREATMENT FOR SMALL CELL LUNG CANCER

CHAPTER 6: TREATMENT FOR SMALL CELL LUNG CANCER CHAPTER 6: TREATMENT FOR SMALL CELL LUNG CANCER INTRODUCTION This chapter provides an overview of treatment for small cell lung cancer (SCLC). Treatment options are presented based on the extent of disease.

More information

Hosts. New Methods for Treating Colorectal Cancer

Hosts. New Methods for Treating Colorectal Cancer Hosts Anees Chagpar MD Associate Professor of Surgical Oncology Francine MD Professor of Medical Oncology New Methods for Treating Colorectal Cancer Guest Expert: Scott, MD Associate Professor in the Department

More information

Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.

Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies

More information

BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I

BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I Overview Why is it important to understand breast cancer? Choosing wisely Appropriateness

More information

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD Epidemiology, Staging and Treatment of Lung Cancer Mark A. Socinski, MD Associate Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of

More information

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need?

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,

More information

Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress

Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy

More information

About chemotherapy for lung cancer

About chemotherapy for lung cancer About chemotherapy for lung cancer This information is about chemotherapy for lung cancer. There are sections on What is chemotherapy? Chemotherapy for small cell lung cancer Chemotherapy for non-small

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description

More information

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.

More information

Multidisciplinary discussion of: Early staged NSCLC

Multidisciplinary discussion of: Early staged NSCLC Multidisciplinary discussion of: Early staged NSCLC 2 different classes of patients Stage IIIA pt2pn2 Stage IIB pt3pn0 2 different classes of patients 50% 40% 30% 20% 10% 3y survival 50% 40% 30% 20% 10%

More information

3.0 With final Comments for presentation at Sub Group Meeting 24. 24.11.10

3.0 With final Comments for presentation at Sub Group Meeting 24. 24.11.10 Guideline for the Treatment of Lung Cancer Version History 2.0 Endorsed by the Governance Committee as treatment of lung cancer 27.07.09 with radiotherapy and chemotherapy. 2.1 Re-written to include the

More information

What is a Stem Cell Transplantation?

What is a Stem Cell Transplantation? What is a Stem Cell Transplantation? Guest Expert: Stuart, MD Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken. I am

More information

Cellular, Molecular, and Biochemical Targets in Breast Cancer

Cellular, Molecular, and Biochemical Targets in Breast Cancer Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm

More information

Appendix One. HER2-positive early breast cancer, its treatment and prognosis

Appendix One. HER2-positive early breast cancer, its treatment and prognosis Appendix One. HER2-positive early breast cancer, its treatment and prognosis Breast cancer and HER2/neu over-expression Health need is one of PHARMAC s nine decision criteria (http://www.pharmac.govt.nz/pdf/231205.pdf

More information

A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on

A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What

More information

Pancreatic Cancer: FDA Approved Treatments and Clinical Trials

Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:

More information